Excedrin Migraine
Company: Bristol-Myers Squibb
Approval Status: Approved January 1998
Treatment for: Mild-to-moderate migraine
Areas: Neurology
| General Information | Clinical Results | Mechanism of Action |
General Information
Bristol-Myers Squibb received approval of its Excedrin Migraine for the treatment of pain associated with mild-to-moderate migraine. It is the first over the counter drug to be approved for this indication.
Clinical Results
In trials involving about 1300 migraineurs, Excedrin Migraine was found safe and effective in relieving migraine pain within 2-to-4 hours of dosing.
Mechanism of Action
Excedrin Migraine contains 250 mg acetaminophen, 250 mg aspirin, and 65 mg caffeine in each tablet. The ingredients are the same as those in Excedrin Extra, which is already on the market, but the product comes with instructions and warnings specific to migraine.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
